
Carasent - Webdoc NO a Litmus Test for Carasent's Extensive Capex Initiatives

Redeye updates its estimates following Carasent's Q1 report and comments on topics ranging from the heavy capex cycle to CEO Dennis Höjer's decision to step down. We expect Webdoc NO to be launched in Q2 2022 and its launch and successive ramp-up will be a litmus test for the Webdoc platform and the current spending levels.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Carasent - Webdoc NO a Litmus Test for Carasent's Extensive Capex Initiatives](#)